Alternative RNA Splicing in the Pathogenesis of GBM
暂无分享,去创建一个
[1] F. Yu,et al. Identification of differential splicing genes in gliomas using exon expression profiling , 2014, Molecular medicine reports.
[2] Hiroshi Yamamoto,et al. RAGE expression in tumor-associated macrophages promotes angiogenesis in glioma. , 2014, Cancer research.
[3] Zongwei Li,et al. The multifaceted regulation and functions of PKM2 in tumor progression. , 2014, Biochimica et biophysica acta.
[4] D. Bates,et al. Hallmarks of alternative splicing in cancer , 2014, Oncogene.
[5] E. Makeyev,et al. Regulation of mRNA Abundance by Polypyrimidine Tract-Binding Protein-Controlled Alternate 5′ Splice Site Choice , 2014, PLoS genetics.
[6] G. Reifenberger,et al. EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. , 2014, The Lancet. Oncology.
[7] D. Scholtens,et al. Lineage-specific splicing of a brain-enriched alternative exon promotes glioblastoma progression. , 2014, The Journal of clinical investigation.
[8] J. C. Love,et al. EGFR variant heterogeneity in glioblastoma resolved through single-nucleus sequencing. , 2014, Cancer discovery.
[9] J. Sarkaria,et al. EGFRvIII stimulates glioma growth and invasion through PKA-dependent serine phosphorylation of Dock180 , 2014, Oncogene.
[10] Hu Zhu,et al. The GLI1 splice variant TGLI1 promotes glioblastoma angiogenesis and growth. , 2014, Cancer letters.
[11] S. Nelson,et al. Targeted Therapy Resistance Mediated by Dynamic Regulation of Extrachromosomal Mutant EGFR DNA , 2014, Science.
[12] P. Taneja,et al. AR-A 014418 Used against GSK3beta Downregulates Expression of hnRNPA1 and SF2/ASF Splicing Factors , 2014, Journal of oncology.
[13] Yu Zhou,et al. De Novo Prediction of PTBP1 Binding and Splicing Targets Reveals Unexpected Features of Its RNA Recognition and Function , 2014, PLoS Comput. Biol..
[14] Zefeng Wang,et al. A day in the life of the spliceosome , 2014, Nature Reviews Molecular Cell Biology.
[15] C. Brennan,et al. Quantitative assessment of intragenic receptor tyrosine kinase deletions in primary glioblastomas: their prevalence and molecular correlates , 2013, Acta Neuropathologica.
[16] D. Maiguel,et al. Alternative Splicing of the RAGE Cytoplasmic Domain Regulates Cell Signaling and Function , 2013, PloS one.
[17] Xingzhong Guo,et al. Identification and expression of a novel MDM4 splice variant in human glioma , 2013, Brain Research.
[18] Jian Zhang,et al. Misregulation of pre-mRNA alternative splicing in cancer. , 2013, Cancer discovery.
[19] D. Haussler,et al. The Somatic Genomic Landscape of Glioblastoma , 2013, Cell.
[20] Lynda Chin,et al. INAUGURAL ARTICLE by a Recently Elected Academy Member:From the Cover: Neutralization of terminal differentiation in gliomagenesis , 2013 .
[21] Douglas L Black,et al. EGFR mutation-induced alternative splicing of Max contributes to growth of glycolytic tumors in brain cancer. , 2013, Cell metabolism.
[22] Shinn-Zong Lin,et al. Aberrant Alternative Splicing Events in Parkinson's Disease , 2013, Cell transplantation.
[23] Ahmed Sadeque,et al. Identification and characterization of alternative exon usage linked glioblastoma multiforme survival , 2012, BMC Medical Genomics.
[24] R. Krahe,et al. PTBP1‐dependent regulation of USP5 alternative RNA splicing plays a role in glioblastoma tumorigenesis , 2012, Molecular carcinogenesis.
[25] A. Krainer,et al. Manipulation of PK-M mutually exclusive alternative splicing by antisense oligonucleotides , 2012, Open Biology.
[26] Carine Maenhaut,et al. Hallmarks of cancer: of all cancer cells, all the time? , 2012, Trends in molecular medicine.
[27] E. Gottlieb,et al. Rocking cell metabolism: revised functions of the key glycolytic regulator PKM2 in cancer. , 2012, Trends in biochemical sciences.
[28] A. Koong,et al. A novel epidermal growth factor receptor variant lacking multiple domains directly activates transcription and is overexpressed in tumors , 2012, Oncogene.
[29] F. Caire,et al. EGFR Soluble Isoforms and Their Transcripts Are Expressed in Meningiomas , 2012, PloS one.
[30] R. Carpenter,et al. Hedgehog pathway and GLI1 isoforms in human cancer. , 2012, Discovery medicine.
[31] I. Pommepuy,et al. Adult diffuse gliomas produce mRNA transcripts encoding EGFR isoforms lacking a tyrosine kinase domain , 2011, International journal of oncology.
[32] M. Roizen,et al. Hallmarks of Cancer: The Next Generation , 2012 .
[33] Derek Y. Chiang,et al. Glioblastoma-derived epidermal growth factor receptor carboxyl-terminal deletion mutants are transforming and are sensitive to EGFR-directed therapies. , 2011, Cancer research.
[34] C. Brennan,et al. Splicing factor hnRNPH drives an oncogenic splicing switch in gliomas , 2011, The EMBO journal.
[35] L. Nie,et al. Expression and prognostic significance of survivin splice variants in diffusely infiltrating astrocytoma , 2011, Journal of Clinical Pathology.
[36] Luigi Coppola,et al. Splicing factor hnRNP A2/B1 regulates tumor suppressor gene splicing and is an oncogenic driver in glioblastoma. , 2011, Cancer research.
[37] Jianren Gu,et al. Identification of an exon 4-deletion variant of epidermal growth factor receptor with increased metastasis-promoting capacity. , 2011, Neoplasia.
[38] M. Russo,et al. Pro-inflammatory gene expression in solid glioblastoma microenvironment and in hypoxic stem cells from human glioblastoma , 2011, Journal of Neuroinflammation.
[39] J. Manley,et al. Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged. , 2010, Genes & development.
[40] Yoshitaka Narita,et al. Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. , 2010, Genes & development.
[41] S. Kalkanis,et al. Heparanase expression of glioma in human and animal models. , 2010, Journal of neurosurgery.
[42] F. White,et al. EGFRvIV: a previously uncharacterized oncogenic mutant reveals a kinase autoinhibitory mechanism , 2010, Oncogene.
[43] P. Lichter,et al. Differentiation Therapy Exerts Antitumor Effects on Stem-like Glioma Cells , 2010, Clinical Cancer Research.
[44] A. Krainer,et al. The alternative splicing repressors hnRNP A1/A2 and PTB influence pyruvate kinase isoform expression and cell metabolism , 2010, Proceedings of the National Academy of Sciences.
[45] Ke Wang,et al. Gli1 is a potential target for alleviating multidrug resistance of gliomas , 2010, Journal of the Neurological Sciences.
[46] Paul S Mischel,et al. Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients. , 2009, Cancer research.
[47] F. Ali-Osman,et al. A novel splice variant of GLI1 that promotes glioblastoma cell migration and invasion. , 2009, Cancer research.
[48] Wen Zhu,et al. Splicing factors PTBP1 and PTBP2 promote proliferation and migration of glioma cell lines. , 2009, Brain : a journal of neurology.
[49] A. Baron,et al. Clinical implementation of soluble EGFR (sEGFR) as a theragnostic serum biomarker of breast, lung and ovarian cancer. , 2009, IDrugs : the investigational drugs journal.
[50] G. Riggins,et al. Glioblastoma cell growth is suppressed by disruption of fibroblast growth factor pathway signaling , 2009, Journal of Neuro-Oncology.
[51] C. Will,et al. The Spliceosome: Design Principles of a Dynamic RNP Machine , 2009, Cell.
[52] E. Nevo,et al. Alternatively spliced Spalax heparanase inhibits extracellular matrix degradation, tumor growth, and metastasis , 2009, Proceedings of the National Academy of Sciences.
[53] K. Baggerly,et al. Splicing factors PTBP 1 and PTBP 2 promote proliferation and migration of glioma cell lines , 2009 .
[54] S. Stamm,et al. Alternative splicing and disease. , 2009, Biochimica et biophysica acta.
[55] R. Nieves-Alicea,et al. Shedding of epidermal growth factor receptor is a regulated process that occurs with overexpression in malignant cells. , 2008, Experimental cell research.
[56] T. Mikkelsen,et al. Increased chemotactic migration and growth in heparanase-overexpressing human U251n glioma cells , 2008, Journal of experimental & clinical cancer research : CR.
[57] Duncan J. Smith,et al. "Nought may endure but mutability": spliceosome dynamics and the regulation of splicing. , 2008, Molecular cell.
[58] J. Sawada,et al. Hypoxia induces expression of a GPI‐anchorless splice variant of the prion protein , 2008, The FEBS journal.
[59] M. Kasper,et al. Novel Human Glioma-associated Oncogene 1 (GLI1) Splice Variants Reveal Distinct Mechanisms in the Terminal Transduction of the Hedgehog Signal , 2008, Journal of Biological Chemistry.
[60] Lili Wan,et al. SMN Deficiency Causes Tissue-Specific Perturbations in the Repertoire of snRNAs and Widespread Defects in Splicing , 2008, Cell.
[61] A. Carter,et al. Identification, classification, and expression of RAGE gene splice variants , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[62] Christoph Straub,et al. A brain-specific SGK1 splice isoform regulates expression of ASIC1 in neurons , 2008, Proceedings of the National Academy of Sciences.
[63] Ru Wei,et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth , 2008, Nature.
[64] G. Ast,et al. Alternative splicing: current perspectives , 2008, BioEssays : news and reviews in molecular, cellular and developmental biology.
[65] T. Mikkelsen,et al. Cloning and characterization of human RTVP-1b, a novel splice variant of RTVP-1 in glioma cells. , 2007, Biochemical and biophysical research communications.
[66] F. Lang,et al. Differential Regulation of Serum- and Glucocorticoid-Inducible Kinase 1 (SGK1) Splice Variants Based on Alternative Initiation of Transcription , 2007, Cellular Physiology and Biochemistry.
[67] S. Friedman,et al. Functional inactivation of the KLF6 tumor suppressor gene by loss of heterozygosity and increased alternative splicing in glioblastoma , 2007, International journal of cancer.
[68] B. Scheithauer,et al. The 2007 WHO classification of tumours of the central nervous system , 2007, Acta Neuropathologica.
[69] Douglas L Black,et al. A post-transcriptional regulatory switch in polypyrimidine tract-binding proteins reprograms alternative splicing in developing neurons. , 2007, Genes & development.
[70] N. Mulherkar,et al. MADD/DENN Splice Variant of the IG20 Gene Is a Negative Regulator of Caspase-8 Activation , 2007, Journal of Biological Chemistry.
[71] A. Krainer,et al. The gene encoding the splicing factor SF2/ASF is a proto-oncogene , 2007, Nature Structural &Molecular Biology.
[72] A. Scott,et al. A phase I clinical trial with monoclonal antibody ch 806 targeting transitional state and mutant epidermal growth factor receptors , 2007 .
[73] Xiuli Jiang,et al. Aberrant splicing of cyclin-dependent kinase-associated protein phosphatase KAP increases proliferation and migration in glioblastoma. , 2007, Cancer research.
[74] S. Barnes,et al. Cav3.1 splice variant expression during neuronal differentiation of Y-79 retinoblastoma cells , 2006, Neuroscience.
[75] R. Salgia,et al. Epidermal Growth Factor Receptor–Mediated Signal Transduction in the Development and Therapy of Gliomas , 2006, Clinical Cancer Research.
[76] G. Fuller,et al. Polypyrimidine tract binding protein and Notch1 are independently re-expressed in glioma , 2006, Modern Pathology.
[77] Dario Neri,et al. Tumor-Targeting Properties of Novel Antibodies Specific to the Large Isoform of Tenascin-C , 2006, Clinical Cancer Research.
[78] K. Jellinger,et al. The alternative splicing of tau exon 10 and its regulatory proteins CLK2 and TRA2‐BETA1 changes in sporadic Alzheimer's disease , 2006, Journal of neurochemistry.
[79] 松下 博和. Identification of glioma-specific RFX4-E and -F isoforms and humoral immune response in patients , 2006 .
[80] S. Friedman,et al. Targeted inhibition of the KLF6 splice variant, KLF6 SV1, suppresses prostate cancer cell growth and spread. , 2005, Cancer research.
[81] H. Mehdorn,et al. Expression of VEGF and its receptors in different brain tumors , 2005, Neurological research.
[82] Wei Zhang,et al. Inactivation of the invasion inhibitory gene IIp45 by alternative splicing in gliomas. , 2005, Cancer research.
[83] M. P. Holloway,et al. Survivin splice variants regulate the balance between proliferation and cell death , 2005, Oncogene.
[84] Martin J. van den Bent,et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.
[85] D. Schaid,et al. A germline DNA polymorphism enhances alternative splicing of the KLF6 tumor suppressor gene and is associated with increased prostate cancer risk. , 2005, Cancer research.
[86] J. Kros,et al. Differential expression of Hela‐type caldesmon in tumour neovascularization: a new marker of angiogenic endothelial cells , 2005, The Journal of pathology.
[87] Aaron M. Beedle,et al. Expression of T‐type calcium channel splice variants in human glioma , 2004, Glia.
[88] W. Jin,et al. Correction of aberrant FGFR1 alternative RNA splicing through targeting of intronic regulatory elements. , 2004, Human molecular genetics.
[89] A. Sieuwerts,et al. Differential expression of splicing variants of the human caldesmon gene (CALD1) in glioma neovascularization versus normal brain microvasculature. , 2004, The American journal of pathology.
[90] Jeon-Soo Shin,et al. Expression of a novel secreted splice variant of the receptor for advanced glycation end products (RAGE) in human brain astrocytes and peripheral blood mononuclear cells. , 2004, Molecular immunology.
[91] H. Kawami,et al. Identification of an Alternatively Spliced RNA for the Ras Suppressor RSU-1 in Human Gliomas , 2002, Journal of Neuro-Oncology.
[92] B. Zoll,et al. Amplification and expression of the epidermal growth factor receptor gene during the progression of neuroepithelial tumours in vivo , 1992, Journal of Neurology.
[93] T. Nilsen. The spliceosome: the most complex macromolecular machine in the cell? , 2003, BioEssays : news and reviews in molecular, cellular and developmental biology.
[94] Y. Kajimoto,et al. Transcriptional expression of survivin and its splice variants in brain tumors in humans. , 2003, Journal of neurosurgery.
[95] W. Jin,et al. Polypyrimidine tract-binding protein down-regulates fibroblast growth factor receptor 1 alpha-exon inclusion. , 2003, Cancer research.
[96] Chi-Ying F. Huang,et al. Molecular characterization of human ninein protein: two distinct subdomains required for centrosomal targeting and regulating signals in cell cycle. , 2003, Biochemical and biophysical research communications.
[97] K. Ozawa,et al. Enhancement of thymidine kinase-mediated killing of malignant glioma by BimS, a BH3-only cell death activator , 2003, Gene Therapy.
[98] Kenneth M. Yamada,et al. CrkI adapter protein modulates cell migration and invasion in glioblastoma. , 2003, Cancer research.
[99] T. Cooper,et al. Pre-mRNA splicing and human disease. , 2003, Genes & development.
[100] A. Godwin,et al. Expression of constitutively activated EGFRvlll in non‐small cell lung cancer , 2003, Cancer science.
[101] Jae-Hoon Kim,et al. Crystal Structure of the Complex of Human Epidermal Growth Factor and Receptor Extracellular Domains , 2002, Cell.
[102] Satoshi O. Suzuki,et al. MAP‐2e, a Novel MAP‐2 Isoform, Is Expressed in Gliomas and Delineates Tumor Architecture and Patterns of Infiltration , 2002, Journal of neuropathology and experimental neurology.
[103] R. Coleman,et al. Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[104] W. Cavenee,et al. Human glioblastoma xenografts overexpressing a tumor-specific mutant epidermal growth factor receptor sensitized to cisplatin by the AG1478 tyrosine kinase inhibitor. , 2001, Journal of neurosurgery.
[105] A. Scott,et al. Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor. , 2001, Cancer research.
[106] A. Scott,et al. Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR. , 2001, Cancer research.
[107] H. Poulsen,et al. The type III epidermal growth factor receptor mutation. Biological significance and potential target for anti-cancer therapy. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.
[108] D. Bigner,et al. EGF mutant receptor vIII as a molecular target in cancer therapy. , 2001, Endocrine-related cancer.
[109] Xue-Qing Wang,et al. Post-transcriptional Regulation of the GLI1 Oncogene by the Expression of Alternative 5′ Untranslated Regions* , 2001, The Journal of Biological Chemistry.
[110] C. James,et al. Comparative genomic sequence analysis and isolation of human and mouse alternative EGFR transcripts encoding truncated receptor isoforms. , 2001, Genomics.
[111] J. Laterra,et al. Glioma inhibition by HGF/NK2, an antagonist of scatter factor/hepatocyte growth factor. , 2000, Biochemical and biophysical research communications.
[112] T. Kislinger,et al. Blockade of RAGE–amphoterin signalling suppresses tumour growth and metastases , 2000, Nature.
[113] G. Fuller,et al. Fibroblast growth factor receptor-1 alpha-exon exclusion and polypyrimidine tract-binding protein in glioblastoma multiforme tumors. , 2000, Cancer research.
[114] S. Howng,et al. Differential expression of four human dynamin-like protein variants in brain tumors. , 2000, DNA and cell biology.
[115] C. James,et al. Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. , 2000, Cancer research.
[116] D. Hanahan,et al. The Hallmarks of Cancer , 2000, Cell.
[117] M. Berger,et al. Suppression of glioblastoma cell growth following antisense oligonucleotide‐mediated inhibition of fibroblast growth factor receptor expression , 1999, Glia.
[118] W. Jin,et al. Redundant Intronic Repressors Function to Inhibit Fibroblast Growth Factor Receptor-1 α-Exon Recognition in Glioblastoma Cells* , 1999, The Journal of Biological Chemistry.
[119] M. Seiki,et al. Regulation of matrix metalloproteinase‐2 (MMP‐2) by hepatocyte growth factor/scatter factor (HGF/SF) in human glioma cells: HGF/SF enhances MMP‐2 expression and activation accompanying up‐regulation of membrane type‐1 MMP , 1999, International journal of cancer.
[120] G. Viale,et al. Identification of a glioblastoma-associated tenascin-C isoform by a high affinity recombinant antibody. , 1999, The American journal of pathology.
[121] B. Badie,et al. In vitro modulation of microglia motility by glioma cells is mediated by hepatocyte growth factor/scatter factor. , 1999, Neurosurgery.
[122] F. Neff,et al. Expression of alternatively spliced mdm2 transcripts correlates with stabilized wild‐type p53 protein in human glioblastoma cells , 1999, International journal of cancer.
[123] A. Strasser,et al. The proapoptotic activity of the Bcl-2 family member Bim is regulated by interaction with the dynein motor complex. , 1999, Molecular cell.
[124] Y. Lazebnik,et al. Identification of an endogenous dominant-negative short isoform of caspase-9 that can regulate apoptosis. , 1999, Cancer research.
[125] S. Feller,et al. Physiological signals and oncogenesis mediated through Crk family adapter proteins , 1998, Journal of cellular physiology.
[126] H. Kataoka,et al. Up-regulation of vascular endothelial growth factor induced by hepatocyte growth factor/scatter factor stimulation in human glioma cells. , 1998, Biochemical and biophysical research communications.
[127] W. Jin,et al. Exon Sequence Is Required for Regulated RNA Splicing of the Human Fibroblast Growth Factor Receptor-1 α-Exon* , 1998, The Journal of Biological Chemistry.
[128] W. Cavenee,et al. Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[129] H. Abe,et al. Short alternative splice transcripts of the mdm2 oncogene correlate to malignancy in human astrocytic neoplasms. , 1998, Cancer research.
[130] B. Stoddard,et al. The allosteric regulation of pyruvate kinase by fructose-1,6-bisphosphate. , 1998, Structure.
[131] Marlys Witte,et al. Scatter factor promotes motility of human glioma and neuromicrovascular endothelial cells , 1998, International journal of cancer.
[132] H. Poulsen,et al. Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.
[133] W. Cavenee,et al. Intracerebral tumor-associated hemorrhage caused by overexpression of the vascular endothelial growth factor isoforms VEGF121 and VEGF165 but not VEGF189. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[134] E. Rosen,et al. Scatter factor/hepatocyte growth factor gene transfer enhances glioma growth and angiogenesis in vivo. , 1997, Laboratory investigation; a journal of technical methods and pathology.
[135] H. Wiley,et al. The Enhanced Tumorigenic Activity of a Mutant Epidermal Growth Factor Receptor Common in Human Cancers Is Mediated by Threshold Levels of Constitutive Tyrosine Phosphorylation and Unattenuated Signaling* , 1997, The Journal of Biological Chemistry.
[136] O. Bogler,et al. A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. , 1996, Cancer research.
[137] N. Maihle,et al. A 1.8 kb alternative transcript from the human epidermal growth factor receptor gene encodes a truncated form of the receptor. , 1996, Nucleic acids research.
[138] W. Cavenee,et al. EGFR gene amplification ‐ rearrangement in human glioblastomas , 1995, International journal of cancer.
[139] M. Kan,et al. Ligand-specific Structural Domains in the Fibroblast Growth Factor Receptor (*) , 1995, The Journal of Biological Chemistry.
[140] M. Kan,et al. Alternately Spliced NH2-terminal Immunoglobulin-like Loop I in the Ectodomain of the Fibroblast Growth Factor (FGF) Receptor 1 Lowers Affinity for both Heparin and FGF-1(*) , 1995, Journal of Biological Chemistry.
[141] M. Dours-Zimmermann,et al. A novel glycosaminoglycan attachment domain identified in two alternative splice variants of human versican. , 1994, The Journal of biological chemistry.
[142] W. Cavenee,et al. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[143] G. Hannon,et al. KAP: a dual specificity phosphatase that interacts with cyclin-dependent kinases. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[144] J. Bruner,et al. Differential expression of two fibroblast growth factor-receptor genes is associated with malignant progression in human astrocytomas. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[145] L. Zardi,et al. Cell-cycle dependent alternative splicing of the tenascin primary transcript. , 1994, Cell adhesion and communication.
[146] S. Werner,et al. Targeted expression of a dominant‐negative FGF receptor mutant in the epidermis of transgenic mice reveals a role of FGF in keratinocyte organization and differentiation. , 1993, The EMBO journal.
[147] P. Humphrey,et al. Structural alterations of the epidermal growth factor receptor gene in human gliomas. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[148] T. Habib,et al. Epidermal growth factor (EGF)-stimulated tyrosine phosphorylation and EGF receptor degradation in cells expressing EGF receptors truncated at residue 973. , 1992, The Journal of biological chemistry.
[149] J. Rubin,et al. Identification of a competitive HGF antagonist encoded by an alternative transcript. , 1991, Science.
[150] P. Humphrey,et al. Deletion-mutant epidermal growth factor receptor in human gliomas: effects of type II mutation on receptor function. , 1991, Biochemical and biophysical research communications.
[151] C. James,et al. Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[152] G. M. Walton,et al. Functional independence of the epidermal growth factor receptor from a domain required for ligand-induced internalization and calcium regulation , 1989, Cell.
[153] R. Coleman,et al. Pharmacokinetics and tumor localization of 131I-labeled anti-tenascin monoclonal antibody 81C6 in patients with gliomas and other intracranial malignancies. , 1989, Cancer research.
[154] P. Humphrey,et al. Amplification and expression of the epidermal growth factor receptor gene in human glioma xenografts. , 1988, Cancer research.
[155] J. Trent,et al. Identification of an amplified, highly expressed gene in a human glioma. , 1987, Science.
[156] D. Burk,et al. On respiratory impairment in cancer cells. , 1956, Science.
[157] O. Warburg. [Origin of cancer cells]. , 1956, Oncologia.
[158] S. Weinhouse. On respiratory impairment in cancer cells. , 1956, Science.